Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23

Benzinga Newsdesk www.benzinga.com Neutral 54.9%

Neg 0% Neu 54.9% Pos 0%

Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.